PortalPublikationenImproved detection of circulating tumor cells in non-metasta...

Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients

Standard

Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. / Kuske, Andra; Gorges, Tobias M; Tennstedt, Pierre; Tiebel, Anne-Kathrin; Pompe, Raisa; Preißer, Felix; Prues, Sandra; Mazel, Martine; Markou, Athina; Lianidou, Evi; Peine, Sven; Alix-Panabières, Catherine; Riethdorf, Sabine; Beyer, Burkhard; Schlomm, Thorsten; Pantel, Klaus.

in: SCI REP-UK, Jahrgang 6, 21.12.2016, S. 39736.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kuske, A, Gorges, TM, Tennstedt, P, Tiebel, A-K, Pompe, R, Preißer, F, Prues, S, Mazel, M, Markou, A, Lianidou, E, Peine, S, Alix-Panabières, C, Riethdorf, S, Beyer, B, Schlomm, T & Pantel, K 2016, 'Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients', SCI REP-UK, Jg. 6, S. 39736. https://doi.org/10.1038/srep39736

APA

Kuske, A., Gorges, T. M., Tennstedt, P., Tiebel, A-K., Pompe, R., Preißer, F., Prues, S., Mazel, M., Markou, A., Lianidou, E., Peine, S., Alix-Panabières, C., Riethdorf, S., Beyer, B., Schlomm, T., & Pantel, K. (2016). Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. SCI REP-UK, 6, 39736. https://doi.org/10.1038/srep39736

Vancouver

Kuske A, Gorges TM, Tennstedt P, Tiebel A-K, Pompe R, Preißer F et al. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. SCI REP-UK. 2016 Dez 21;6:39736. https://doi.org/10.1038/srep39736

Bibtex

@article{18da174a8772496e82f280e93a0cb9f8,
title = "Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients",
abstract = "The relevance of blood-based assays to monitor minimal residual disease (MRD) in non-metastatic prostate cancer (PCa) remains unclear. Proving that clinically relevant circulating tumor cells (CTCs) can be detected with available technologies could address this. This study aimed to improve CTC detection in non-metastatic PCa patients by combining three independent CTC assays: the CellSearch system, an in vivo CellCollector and the EPISPOT. Peripheral blood samples from high-risk PCa patients were screened for CTCs before and three months after radical prostatectomy (RP). Combining the results of both time points, CTCs were detected in 37%, 54.9% and 58.7% of patients using CellSearch, CellCollector and EPISPOT, respectively. The cumulative positivity rate of the three CTC assays was 81.3% (87/107) with 21.5% (23/107) of patients harboring ≥5 CTCs/7.5 ml blood. Matched pair analysis of 30 blood samples taken before and after surgery indicated a significant decrease in CTCs captured by the CellCollector from 66% before RP to 34% after therapy (p = 0.031). CTC detection by EPISPOT before RP significantly correlated with PSA serum values (p < 0.0001) and clinical tumor stage (p = 0.04), while the other assays showed no significant correlations. In conclusion, CTC-based liquid biopsies have the potential to monitor MRD in patients with non-metastatic prostate cancer.",
author = "Andra Kuske and Gorges, {Tobias M} and Pierre Tennstedt and Anne-Kathrin Tiebel and Raisa Pompe and Felix Prei{\ss}er and Sandra Prues and Martine Mazel and Athina Markou and Evi Lianidou and Sven Peine and Catherine Alix-Panabi{\`e}res and Sabine Riethdorf and Burkhard Beyer and Thorsten Schlomm and Klaus Pantel",
year = "2016",
month = dec,
day = "21",
doi = "10.1038/srep39736",
language = "English",
volume = "6",
pages = "39736",
journal = "SCI REP-UK",
issn = "2045-2322",
publisher = "NATURE PUBLISHING GROUP",

}

RIS

TY - JOUR

T1 - Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients

AU - Kuske, Andra

AU - Gorges, Tobias M

AU - Tennstedt, Pierre

AU - Tiebel, Anne-Kathrin

AU - Pompe, Raisa

AU - Preißer, Felix

AU - Prues, Sandra

AU - Mazel, Martine

AU - Markou, Athina

AU - Lianidou, Evi

AU - Peine, Sven

AU - Alix-Panabières, Catherine

AU - Riethdorf, Sabine

AU - Beyer, Burkhard

AU - Schlomm, Thorsten

AU - Pantel, Klaus

PY - 2016/12/21

Y1 - 2016/12/21

N2 - The relevance of blood-based assays to monitor minimal residual disease (MRD) in non-metastatic prostate cancer (PCa) remains unclear. Proving that clinically relevant circulating tumor cells (CTCs) can be detected with available technologies could address this. This study aimed to improve CTC detection in non-metastatic PCa patients by combining three independent CTC assays: the CellSearch system, an in vivo CellCollector and the EPISPOT. Peripheral blood samples from high-risk PCa patients were screened for CTCs before and three months after radical prostatectomy (RP). Combining the results of both time points, CTCs were detected in 37%, 54.9% and 58.7% of patients using CellSearch, CellCollector and EPISPOT, respectively. The cumulative positivity rate of the three CTC assays was 81.3% (87/107) with 21.5% (23/107) of patients harboring ≥5 CTCs/7.5 ml blood. Matched pair analysis of 30 blood samples taken before and after surgery indicated a significant decrease in CTCs captured by the CellCollector from 66% before RP to 34% after therapy (p = 0.031). CTC detection by EPISPOT before RP significantly correlated with PSA serum values (p < 0.0001) and clinical tumor stage (p = 0.04), while the other assays showed no significant correlations. In conclusion, CTC-based liquid biopsies have the potential to monitor MRD in patients with non-metastatic prostate cancer.

AB - The relevance of blood-based assays to monitor minimal residual disease (MRD) in non-metastatic prostate cancer (PCa) remains unclear. Proving that clinically relevant circulating tumor cells (CTCs) can be detected with available technologies could address this. This study aimed to improve CTC detection in non-metastatic PCa patients by combining three independent CTC assays: the CellSearch system, an in vivo CellCollector and the EPISPOT. Peripheral blood samples from high-risk PCa patients were screened for CTCs before and three months after radical prostatectomy (RP). Combining the results of both time points, CTCs were detected in 37%, 54.9% and 58.7% of patients using CellSearch, CellCollector and EPISPOT, respectively. The cumulative positivity rate of the three CTC assays was 81.3% (87/107) with 21.5% (23/107) of patients harboring ≥5 CTCs/7.5 ml blood. Matched pair analysis of 30 blood samples taken before and after surgery indicated a significant decrease in CTCs captured by the CellCollector from 66% before RP to 34% after therapy (p = 0.031). CTC detection by EPISPOT before RP significantly correlated with PSA serum values (p < 0.0001) and clinical tumor stage (p = 0.04), while the other assays showed no significant correlations. In conclusion, CTC-based liquid biopsies have the potential to monitor MRD in patients with non-metastatic prostate cancer.

U2 - 10.1038/srep39736

DO - 10.1038/srep39736

M3 - SCORING: Journal article

C2 - 28000772

VL - 6

SP - 39736

JO - SCI REP-UK

JF - SCI REP-UK

SN - 2045-2322

ER -